EpiBone raised an undisclosed amount in a funding round led by Kendall Capital Partners to accelerate its ongoing pipeline development efforts.
EpiBone raised an undisclosed amount in a funding round led by Kendall Capital Partners to accelerate its ongoing pipeline development efforts.
11/11/24, 10:13 AM
Location
brooklynIndustry
biotechnology
Investors
Emv Capital, Life Span Vision Ventures, Kendall Capital Partners
EpiBone, a NYC-based regenerative medicine company, raised an undisclosed amount in funding. The round was led by Kendall Capital Partners, with participation from LifeSpan Vision Ventures, EMV Capital, and others.
Company Info
Location
760 parkside avenue, suite 322
brooklyn, new york, united states
Additional Info
EpiBone is a revolutionary bone reconstruction company that allows patients to “grow their own bone”. EpiBone’s pioneering technology utilizes a scan of the patient’s bone defect and the patient’s own stem cells to construct and cultivate a defect-specific autologous-like bone graft. EpiBone is strategically positioned to provide a superior bone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year.